Enalapril Orodispersible Minitablet
Small molecule
Enalapril Orodispersible Minitablet is one of 86 small molecule programs targeting Heart Failure. It is currently in development.
3
Indications
3
Total Trials
0
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Amidate
PfizerPreclinical
Brethine
SanofiPreclinical
Savaysa
Daiichi SankyoPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Xifaxan
SSalix
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Coumadin
AAbbott
Preclinical
Neo-Synephrine
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dilated Cardiomyopathy1 trial
Congenital Heart Disease1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- EEthicare GmbH